Hepatocellular Carcinoma, Steroid Hormones and Metalloproteases

Noemí Eiró, Belen Fernandez-Garcia, Antonio Altadill, Luis O. González and Francisco J. Vizoso

Additional information is available at the end of the chapter

<http://dx.doi.org/10.5772/56877>

1. Introduction

Liver cancer is the fifth and seventh most frequently diagnosed cancer worldwide in men and women, respectively, but the second most frequent cause of cancer death in men [1]. In addition, hepatocellular carcinoma (HCC) represents the major histological subtype of primary liver cancers, accounting up to 90% of the total liver cancer burden worldwide [2]. The incidence of HCC has increased significantly over the past 10 years and is expected to increase because of the actual high prevalence of viral hepatitis C-seropositive individuals and also because of the known long latency period to HCC development from the initial hepatitis C virus (HCV) infection, which may take 2-3 decades [3]. Despite of the varied treatment options, the prognosis of HCC remains poor. Thus, estimated 5-year survival rates are in the range of 26% to 50%, and disease-free survival is 13% to 29% [4]. At present, systemic chemotherapy is quite ineffective in HCC treatment, and is also known to express the multidrug-resistance gene MDR-1 [5]. Therefore, is necessary to identify and characterize molecular abnormalities of clinical significance in HCC. Besides the heterogeneity of different HCC subtypes, these tumors may use different cellular pathways and oncogenic mechanisms at different development stages, and this is of essential importance to develop biologically-based clinical trials.

2. Steroid hormone receptors and hepatocellular carcinoma

Although sex differences in liver cancer may be attributed to differences in lifestyle [6-8], there are several epidemiological and experimental studies suggesting that HCC might be, in part, hormone-related. Liver cancer is predominantly a male disease, with approximately three

times higher incidence and mortality among men than women [9]. This male predominance is further supported by the fact that chronic liver disease progresses more rapidly to cirrhosis in males than in females, and therefore cirrhosis-derived HCC is largely seen in men and postmenopausal women disease [10].

The role of estrogens in modulating morphological and physiological features of liver became evident in early 1970s when a possible correlation between occurrence of hepatic neoplasms and use of oral contraceptives was suggested [11-12]. On the basis of these data, several *in vitro* and *in vivo* studies have explored the importance of sex hormones in HCC. Animal model-based studies indicate that sex hormones play a key role in tumor progression, showing that ovarian estrogens protect against tumor progression, whereas androgens promote tumorigenesis [13-15]. It has been reported that the protective effect of estrogens against chemically induced liver tumors is mediated by prolactin (PRL) through liver prolactin receptors (PRLR) [16-18]. Nevertheless, the precise role of male and female sex hormones and their receptors in HCC remains still poorly understood. There is not enough information regarding the mechanism of estrogen and androgen in HCC.

Estrogen and androgen mediate their biological functions through binding to their specific receptors, the estrogen receptor (ER) and the androgen receptor (AR). Both ER and AR belong to the nuclear receptors family that, as transcription factors, regulate the expression level of several genes such as those involved in triggering immune responses, cell proliferation and apoptosis [19-21]. Therefore, sex hormones play a key role in normal physiology of organs other than these of the reproductive system.

Variable expressions of ER and AR has been found in normal liver and HCC using different methods, such as immunohistochemistry, enzyme-immuno assays, or determining mRNA levels (Table 1 and Table 2 give the details of these studies for ER and AR, respectively), which indicate a relationship between sex hormones and pathogenesis of HCC. The percentage of positivity for these receptors varied between the different studies [22]. These differences may be due to several methodological aspects, such as differences in the origin of the studied patients populations, sample types or technologies determining the receptor expression. In a recent study, we determined the expression of sex hormones receptors in 31 HCC patients by immunohistochemistry using tissue micro-arrays technology [23]. Our results demonstrate a wide variability in the immunohistochemical values for steroid receptors among HCCs: 67.7% of tumors stained positively for AR, 51.6% for ER and 83.8% for progesterone receptor (PgR), but, among the positive cases, immunostaining score values for each protein were largely variable.

Reference	Protein /mRNA	Type of liver tissue	Method	Localization	n	% positive cases	Country	Year
[122]	ER protein	Normal	BA	cytosolic	4	100	United Kingdom	1978
[123]	ER protein	Normal	BA	-	3	100	Germany	1978
[124]	ER protein	Normal	BA	-	2	100	United States	1982

Reference	Protein /mRNA	Type of liver tissue	Method	Localization	n	% positive cases	Country	Year
[125]	ER protein	Normal	BA	-	6	100	Germany	1982
[126]	ER protein	Normal	BA	-	6	100	United States	1983
[127]	ER protein	Normal	BA	cytosolic and nuclear	4	100	United Kingdom	1983
[128]	ER protein	Surrounding	BA	cytosolic	30	43	Japan	1986
[129]	ER protein	Non-cancerous	BA	cytosolic and nuclear	7	43	Japan	1986
[130]	ER protein	Non-cirrhotic	EIA	cytosolic	12	12	Japan	1987
[131]	ER protein	Normal		-	2	2	Japan	1988
[132]	ER protein	Surrounding	BA	cytosolic	17	65	Japan	1989
[133]	ER protein	Surrounding			22	64	Japan	1989
[134]	ER protein	Surrounding	BA	cytosolic	5	100	Japan	1990
[135]	ER protein	Normal	BA		9	9	United States, Italy	1991
[52]	ER protein	Non-cancerous	BA	cytosolic	26	42	Spain	1993
[136]	ER mRNA	Non-cancerous	ISH		13	54	Italy	1993
[137]	ER mRNA	Peritumoral	RT-PCR	-	32	88	Korea	2006
[124]	ER protein	HCC	BA	cytosolic	5	100	United States	1982
[127]	ER protein	HCC	BA	cytosolic and nuclear	5	100	United Kingdom	1983
[138]	ER protein	HCC	IHC	cytosolic	10	10	Singapore	1984
[128]	ER protein	HCC	BA	cytosolic	30	40	Japan	1986
[139]	ER protein	HCC	BA	cytosolic and nuclear	8	13	Japan	1986
[130]	ER protein	HCC	EIA	cytosolic	13	38	Japan	1987
[132]	ER protein	HCC	BA	cytosolic	19	37	Japan	1989
[24]	ER protein	HCC	BA	cytosolic	66	39	Japan	1990
[134]	ER protein	HCC	BA	cytosolic	6	17	Japan	1990
[140]	ER protein	HCC	BA	cytosolic	21	48	Japan	1991
[141]	ER protein	HCC	BA	cytosolic and nuclear	9	89	United States, Italy	1991
[135]	ER protein	HCC	BA	cytosolic and nuclear	9	89	United States, Italy	1991

Reference	Protein /mRNA	Type of liver tissue	Method	Localization	n	% positive cases	Country	Year
[52]	ER protein	HCC	EIA	cytosolic	26	15	Spain	1993
[136]	ER protein	HCC	IHC	-	15	0	Italy	1993
[136]	ER mRNA	HCC	ISH	-	15	73	Italy	1993
[142]	ER mRNA	HCC	RT-PCR	-	14	57	Italy	1995
[25]	ER protein	HCC	EIA	cytosolic	33	39	Germany	1997
[143]	ER protein	HCC	IHC	cytosolic	71	24	China	1997
[144]	ER mRNA	HCC	RT-PCR	-	40	70	Italy	1998
[145]	ER mRNA	HCC	RT-PCR	-	42	60	Italy	2003
[146]	ER protein	HCC	IHC	cytosolic and nuclear	45	71	United States/ Koreans	2004
[147]	ER protein	HCC	IHC	-	28	39	China	2004
[147]	ER mRNA	HCC	RT-PCR	-	28	89	China	2004
[137]	ER mRNA	HCC	RT-PCR	-	32	100	Korea	2006
[148]	ER protein	HCC	IHC	-	66	5	Mexico	2007
[23]	ER protein	HCC	IHC	Nuclear	31	52	Spain	2007

ER: Estrogen receptor; HCC: Hepatocellular carcinoma; BA: Binding assay; EIA: Enzyme immunoassay; ISH: *In situ* hybridization; RT-PCR: Reverse transcriptase-polymerase Chain reaction for ERα wild type; IHC: Immunohistochemistry.

Table 1. Estrogen expression in normal liver and hepatocellular carcinoma tissue samples.

Reference	Protein /mRNA	Type of liver tissue	Method	Localization	n	% positive cases	Country	Year
[127]	AR protein	Normal	BA	cytosolic and nuclear	4	0	United Kingdom	1983
[139]	AR protein	Non-cancerous	BA	cytosolic and nuclear	6	17	Japan	1986
[132]	AR protein	Non-cancerous	BA	cytosolic	17	65	Japan	1989
[133]	AR protein	Surrounding			21	33	Japan	1989
[134]	AR protein	Surrounding	BA	cytosolic	10	80	Japan	1990
[135]	AR protein	Normal	-	-	9	100	United States, Italy	1991
[137]	AR mRNA	Peritumoral	RT-PCR		32	100	Korea	2006

Reference	Protein /mRNA	Type of liver tissue	Method	Localization	n	% positive cases	Country	Year
[127]	AR protein	HCC	BA	cytosolic and nuclear	5	100	United Kingdom	1983
[138]	AR protein	HCC	IHC	cytosolic	10	50	Singapore	1984
[149]	AR protein	HCC	BA	cytosolic	19	74	Japan	1985
[150]	AR protein	HCC	BA	cytosolic and nuclear	5	100	United Kingdom	1985
[139]	AR protein	HCC	BA	cytosolic and nuclear	8	50	Japan	1986
[151]	AR protein	HCC	BA	cytosolic	13	100	United Kingdom	1988
[132]	AR protein	HCC	BA	cytosolic	19	37	Japan	1989
[27]	AR protein	HCC	BA	cytosolic	45	69	Japan	1989
[134]	AR protein	HCC	BA	cytosolic	11	64	Japan	1990
[140]	AR protein	HCC	BA	cytosolic	21	86	Japan	1991
[135]	AR protein	HCC	BA	cytosolic and nuclear	9	100	United States, Italy	1991
[152]	AR protein	HCC	BA	cytosolic	5	100	Japan	1992
[52]	AR protein	HCC	BA	cytosolic	26	54	Spain	1993
[28]	AR protein	HCC	BA	cytosolic	43	65	Spain	1995
[23]	AR protein	HCC	IHC	nuclear	31	68	Spain	2007
[129]	AR mRNA	HCC	ISH	-	22	73	Italy	1994
[153]	AR mRNA	HCC	RT-PCR	-	38	89	Italy	2002
[137]	AR mRNA	HCC	RT-PCR	-	32	100	Korea	2006

AR: Androgen receptor; HCC: Hepatocellular carcinoma; BA: Binding assay; ISH: *In situ* hybridization; RT-PCR: Reverse transcriptase-polymerase Chain reaction; IHC: Immunohistochemistry.

Table 2. Androgen receptor expression in normal liver and hepatocellular carcinoma tissue samples.

Several studies have analyzed the relationship between ER or AR and clinicopathological parameters from HCCs patients and their clinical outcome (Table 3). In general, ER expression was associated with higher tumor aggressiveness and/or worse prognosis in HCC patients [24-26], whereas AR expression was negatively associated with recurrence [27-29]. It is remarkable the finding that the presence of the ER α variant has been associated with shortened overall survival in patients with resectable HCC [30,26].

3. Steroid receptors and hepatitis virus

It is of special interest the interaction between sex estrogen receptors and viral proteins in hepatitis B virus (HBV) and hepatitis C virus (HCV)-induced HCC. It has been reported that a HBV protein (HBx) interacts with ER α . HBx is a multifunctional protein involved in neoplastic transformation in cultured cells and in HCC induction in transgenic mice. Both HBx and vER α (Delta 5 deletion variant of ER α) have additive effects on suppressing ER α trans-activation [31]. In addition, it was reported that tamoxifen inhibits ER α actions and suppresses HCV genome replication [32], which may be of potential interest to develop new anti-HCV strategies based on anti-ER drugs. On the other hand, higher serum androgen concentrations or a specific AR gene, which leads to higher AR activities, have also been associated to higher risk in HBV-mediated HCC [33-34]. Likewise, it has been reported that the combination of male gender and HBV infection had a significant synergistic effect on HCC progression [35]. Most recently, Ming-Heng *et al.* found that hepatic AR increases the HBV viral titer by enhancing HBV RNA transcription through direct binding to the androgen response element near the viral core promoter. This activity forms a positive feedback mechanism with the cooperation of its downstream target, the HBx protein, to promote hepatocarcinogenesis. In addition in these same study administration of a chemical compound that selectively degrades AR, ASC-J9, was able to suppress HCC tumor size in a transgenic HBV mouse model that developed HCC upon exposure to a low dose of N'-N'-diethylnitrosamine (DEN). These results demonstrate that targeting the AR, rather than the androgen, could be developed as a new therapy to battle HBV-induced HCC [36].

Reference	Protein / mRNA	clinicopathological parameters	Correlation	n	year	country
[128]	ER protein	Serum alpha-fetoprotein, HBV profile, tumor histology, carcinoembryonic antigen	-	30	1986	Japan
[132]	ER and AR protein	Serum alpha-fetoprotein, Histopathology, HBV markers	-	19	1989	Japan
[24]	ER protein	Sex, age, alcohol consumption, hepatic function, other liver disease, tumor size, hepatic resection, tumor recurrence, long-term survival rate	ER- patients showed higher rate of resection and larger tumor size	66	1990	Japan
[49]	ER and AR protein	Local recurrence	AR expression was associated with intrahepatic recurrence	78	1995	Japan
[25]	ER protein	Survival after curative resection	ER+ tumor have a negative effect on patient survival after curative resection	28	1997	Germany

Reference	Protein / mRNA	clinicopathological parameters	Correlation	n	year	country
[26]	ER mRNA	Survival	Wild type ERs tumors showed long survival in patients	96	2000	Italy
[132]	AR protein	Recurrence and survival rate	AR+ patients showed higher recurrence rates. AR- patients showed better survival rates.	45	1989	Japan
[28]	AR protein	Tumor size and tumor recurrence	AR expression correlated with smaller tumor size. Higher tumor recurrence in AR+ surrounding tissues.	43	1995	Spain
[29]	AR protein	Tumor size and survival time	AR+ tumor correlated with higher tumor size and lower survival rates.	32	1998	China

ER: Estrogen receptor; AR: Androgen receptor

Table 3. Relationship between estrogen or androgen receptors with clinicopathological parameters and clinical outcome of patients with HCC.

4. Endocrine therapy in hepatocellular carcinoma

Considering both the epidemiologic and the experimental data supporting the sex steroids influence in growth and progression from HCCs, different clinical studies analyzed if endocrine therapy could be interesting in advanced disease. Table 4 gives details of some of these studies. Trials using several agents, such as the anti-estrogen tamoxifen, megestrol acetate, progestin, the gonadotropin releasing hormone (GnRH) agonist leuporelin and the anti-androgen flutamide have been uniformly disappointing [37-40]. At present, experts have concluded that hormonal manipulation should not be a part of the current management of patients with HCC [41-42]. However, it is possible that the rational design of an endocrine therapy requires a more complete understanding of the role of sex hormones in the tumorigenic process and how hormones and organ systems interact during this process [18], in addition to careful selection of the new studies patient populations, since patient stratification based on gender may uncover signals of activity of hormonal therapy in these settings. Notably, it has been shown that the anti-estrogens tamoxifen and raloxifene, behave differently in different tissues, producing estrogen-agonist activity in one tissue while behaving as an antagonist in another [43-44]. In addition, *in vitro* studies in the liver cell line Hep3B, indicate that raloxifene induces the insulin-like growth factor (IGF-I) gene transcription, whereas estradiol or tamoxifen inhibits it [45]. On the other hand, the lack of hormone efficacy in these clinical studies, in terms of tumor growth and survival, could be due to either a low expression of ER or AR in HCC or to mutated receptors expression. Therefore, further studies will be necessary to

improve patient selection on the basis of gender, ER tumor expression and their functional status. With regard to this latter aspect, considering that PgR is an estrogen inducible protein, it led us to consider that this steroid receptor could be a possible marker of ER functional status in HCC, to select candidate patients to an anti-estrogenic therapy. In addition, we demonstrated that PgR expression have a prognostic implication in patients with resected HCCs, being a factor associated with better prognostic [23], which is a clinical finding previously demonstrated in breast cancer [46-47]. This finding is very important considering also our reported positive association between PgR expression and HCV infection [23], which represents an increasing aetiology of HCC in our patient's population [3].

Several data suggest that blocking AR may be interesting in HCC therapy. Studies in animal models suggest that increased hepatic AR expression correlated with accelerated tumor development [48], or even AR expression was associated with intrahepatic recurrence in HCC [49]. However, AR expression has also been reported to be associated to small tumor size, but not with a higher rate of recurrence [28]. More recent data indicate that suppression of androgen or AR signals also led to an increase in the number of infiltrating cells, such as macrophages as well as B or T-cells [50], which shows diverse and important roles in the promotion of HCC tumorigenicity [51]. Although there is few data on the effect of anti-androgens in HCC patients, it has been suggested that anti-androgen therapy may have some benefit in patients with androgen-positive tumors [52]. Likewise, recently it has been reported that a multicenter trial with anti-androgens in HCC male patients, has been interrupted because of digestive side effects [39]. Nevertheless, further studies will be necessary to assess whether AR status may be a useful marker to select more accurately candidate patients to further anti-androgenic therapies. Notably, it has been reported that expression of androgen-induced proteins, such as apolipoprotein D or Zinc-alpha2-glycoprotein, is associated with poor prognosis in HCC.

Apolipoprotein D (ApoD) is an androgen-induced protein increased in both prostate and breast cancer cells [53-55]. A report of Utsunomiya *et al.* showed that low ApoD expression correlated significantly with less-differentiated HCCs and therefore with a worse prognosis of patients [56]. However, we did not found any relationship between ApoD expression and the hormonal receptor status in HCC [23]. Nevertheless, further studies will be also necessary in order to assess the possible value of ApoD as a biological marker of androgen response and/or other hormonal pathways in HCC. Thus, with regard to this latter aspect, although ApoD is an androgen-regulated protein, it can also be induced by other hormonal steroids or substances such as glucocorticoids, retinoic acid or 1,25-dihydroxyvitamin D₃, that might be involved in the regulation of this ApoD in human tumors [54,57-58]. This is relevant since it has been described that both retinoid and glucocorticoid receptors have been also detected in HCC [59-60], and that preliminary data show that retinoids are considered of clinical interest as cancer chemotherapeutic agents in advanced HCC [61].

Zinc-alpha2-glycoprotein (ZA2G) is also an androgen-induced protein increased in breast cancer [58,62]. Recently, ZA2G expression was found to be decreased in HCC tissues at both mRNA and protein levels. Moreover, low expression of ZA2G was notably more prevalent in

Hormone Receptor/ mRNA	Valuation parameters	Treatment	n	Clinical outcomes	Year	Reference
ER (previous patient group)	Tumor growth	Progestin	5	Tumor regression in 2	1982	[124]
NA	Anti-tumoral effect. Survival.	Tamoxifen 20 mg twice daily.	33	No effect on the tumor, in 8 remained stable between 5 and 13 months. Prolonged survival in 4 patients (over 18 months).	1990	[154]
NA	Anti-tumoral effect. Survival.	Tamoxifen 20 mg daily.	120 (placebo = 62)	No effect on the tumor. No effect on survival.	1995	[155]
Wild type and variant ER RNA m	Tumor growth.	Tamoxifen 80 mg daily in patients with wild-ERs or megestrol 160 mg daily in patients with variant ERs.	8 patients, 4 with wild ERs and 4 with variant ERs.	Tumor regression to half size in patients with wild type ERs following tamoxifen treatment. Megestrol slowed down tumor growth in tumors with variant ERs.	1996	[30]
ER y PR	Survival.	Tamoxifen.	119 (placebo = 58)	No effects on survival, regardless of the type of receptor expressed.	2000	[156]
Variant ER mRNA.	Tumor growth. Survival.	Megestrol 160 mg daily.	45 (placebo = 24).	Significantly slowed down tumor growth and improved survival in treated patients than placebo group.	2001	[157]
NA	Survival. Quality of life.	Tamoxifen 120 mg or 60 mg daily.	329	No effect on survival or on quality of life. Deleterious effects with the higher dose.	2002	[158]

ER= Estrogen receptor. NA=information not available. PR= Progesterone Receptor.

Table 4. Results of hormonal treatment in hepatocellular carcinoma

patients with poor tumor differentiation, advanced liver cirrhosis, high serum alpha fetoprotein (AFP) level and shorter survival time. These results suggest that ZA2G may be a promising novel prognostic biomarker for HCC [63], and advocate for the need for validation studies.

Recent data indicates that estrogens attenuate tumor progression in HCC *in vivo* by reducing tumor cell invasion, arresting cell cycle progression, and promoting apoptosis, which is characterized by an increased expression of cleaved caspase-3, and by a decrease in the expression of Proliferating Cell Nuclear Antigen (PCNA), cyclin A, cyclin D1, Bcl-2, and matrix metalloproteases (MMP) 2 and 9 [64]. It is relevant the data indicating that steroid hormones, such as estrogens, may inhibit MMPs in several experimental models [65-67]. This may be of great importance due to MMPs are proteolytic enzymes which participate in the degradation of the stromal connective tissue and basement membrane component, therefore facilitating tumor invasion and metastasis. Here, we show a negative relationship between ER expression and MMP2, MMP-9 or MMP-11 expression in HCC (Figure 1).

Figure 1. Relationship between ER expression and median score values of MMP2, MMP-9 or MMP-11 expression in HCC.

5. Metalloproteases and their inhibitors

Degradation of the stromal connective tissue and basement membrane components are key elements in tumor invasion and metastasis. Some components of the extracellular matrix, particularly interstitial collagens, are very resistant to proteolytic attacks, being degraded only by matrix metalloproteases (MMPs) [68].

The human MMP family currently consists of 28 members of homologous zinc-dependent endopeptidases, which can be divided into eight structural classes or, based on their substrate specificity and primary structure, into the more familiar subgroups of collagenases (MMP-1, -8 and -13), gelatinases (MMP-2 and -9), stromelysins (MMP-3, -10, -11), membrane-associated MMPs (MMP-14, -15, -16, -17, -23, -24, -25) and other novel MMPs [69-71]. MMPs are synthe-

sized as inactive zymogens, which are then activated predominantly pericellularly by other MMPs or by serine-proteases. MMPs' activity is specifically inhibited by the so-called tissue inhibitors of metalloproteases (TIMPs). Currently, four different TIMPs are known to exist: TIMP-1, -2, -3 and -4. In addition, there are other two additional aspects conferring relevance to this enzymatic system in cancer biology. First, MMPs are able to impact on tumor cell behavior *in vivo* as a consequence of their ability to cleave growth factors, cell surface receptors, cell adhesion molecules, or chemokines/cytoquines [72-77]. Furthermore, by cleaving proapoptotic factors, MMPs may induce a more aggressive phenotype via generation of apoptotic resistant cells [78]. MMPs may also regulate angiogenesis in cancer, both positively through their ability to mobilize or activate proangiogenic factors [79-80], and negatively via generation of angiogenesis inhibitors, such as angiostatin and endostatin, cleaved from large protein precursors [81-83]. Second, it is now assumed that TIMPs are multifactorial proteins also involved in the induction of proliferation and the inhibition of apoptosis [84-85].

Previous studies have shown the expression of several MMPs in HCC [86-100]. These findings have a great interest because HCC is characterized by a disposition for vascular invasion and high metastatic potential, thus leading to high incidence of early postoperative recurrence and poor survival [101-102]. Although there is no basal membrane in the liver, HCC cancer cells grow surrounded by extracellular matrix proteins secreted as a consequence of cirrhosis, and therefore proteolytic activity is required to allow HCC cells to penetrate and cross over such tissue boundaries [103]. In fact, several studies have suggested the significance of some MMPs in the malignant behavior of HCC, such as MMP-2 [86-93], MMP-7 [88,94], MMP-9 [95-97,91,93,104], MMP-12 [105] or MMP-14 (MT1-MMP) [98,91,99-100]. In these studies, MMPs were associated with several parameters indicative of tumor aggressiveness and poor prognosis, although the cellular type expressing each factor (tumor cell and/or peritumor stromal cell) was not specifically considered.

There are few available data referring to the integrated expression of these factors in relation with HCC. In this context, we have described new findings about MMPs and TIMPs expressions in HCC, together with an important expression by tumor stromal cells, as well as their clinical relevance. It is known that MMPs expression in neoplastic tissues is high due to regulation, in a paracrine manner, by growth factors and cytokines secreted by either tumor or stromal cells [106]. Nevertheless, high MMPs and TIMPs expression by HCCs tissues may be also due to the interplay between transformed cells and their microenvironment, particularly the surrounding extracellular matrix. In human livers, fibrogenesis underlies the development of HCCs in at least 90% of cases [107], and HCC is typically surrounded by a fibrous capsule at an early stage [108]. In addition, several studies have shown that some MMPs (MMP-1, -2, -9 and -13) and TIMPs (TIMP-1 and -2) are involved in the liver fibrosis processes [90,109-112]. It has been demonstrated that extracellular matrix deposition induces overexpression of MMPs and TIMPs, such as MMP-2, secreted by human mesenchymal cells but also by hepatoma cells [87].

Recently we reported that immunostaining for MMPs and TIMPs was localized predominantly in tumor cells, but also in peritumor stromal cells in a significant percentage of cases. However,

we found no stromal expression of MMPs or TIMPs in normal liver samples [113]. We also found a positive and noteworthy association between MMP-1 expression by fibroblasts or by mononuclear inflammatory cells (MICs) and a larger tumor size. In addition, our data showed that MMP-1 expression by stromal fibroblasts, as well as the expression of MMP-13, TIMP-1 and 2, by MICs, were significantly associated with a shorter overall survival (Figure 2) [113].

Figure 2. Kaplan-Meier survival curves as function of the expression by fibroblasts cells of MMP-1 (A); expression by MIC of MMP-13 (B), TIMP-1 (C) and TIMP-2 (D).

There are discrepancies between different studies regarding the prognostic significance of several of these factors in HCC, such as MMP-9 and MMP-2 expression in stromal compartments [113,93]. Nevertheless, it is worth considering the existence of possible differences in MMPs or TIMPs expression between different patient's populations. Thus, for example, in Asian countries HCC originates more frequently in healthy liver tissues, with less incidence of cirrhosis, than in Europe, whereas in the Mediterranean area as well as in the North American countries liver HCC only develops in chronically injured livers, where altered turn-over and increased deposition of ECM proteins has been described. In a such environment, upregulation of MMPs and TIMPs has been reported and it is possible for them to play an important role in the rearrangement of the liver tissue architecture an aspect that could influence the different expression pattern of MMPs and TIMPs in stromal HCC cells [110,114].

On the other hand, a decrease on TIMP-2 and -3 expression has been reported to be associated with invasion and metastases in HCC [115-116]. Certainly, if TIMPs inhibit MMPs *in vivo*, it should be expected that high levels of these inhibitors would prevent tumor progression and thus to be related with good outcome in cancer patients. However, TIMPs are multifunctional proteins that in addition to its MMP-inhibitory effect also shown distinct tumor-stimulatory functions, such as the induction of proliferation and the inhibition of apoptosis [84]. Thus, it is of note that TIMP-1 and -2 expressions by stromal cells were associated with shortened overall survival[113]. Accordingly, it has been reported that TIMP-1 overexpression leads to an increase of hepatoma cells migration [117], and also that it is associated with invasion and metastases in HCC [115,117].

Figure 3. Graphical representation of two-dimensional unsupervised hierarchical clustering results on immunohistochemistry expression (score values) profile in 10 proteins (MMPs and TIMPs) in 30 samples of HCC tissue. Rows: tumor samples; columns: MMPs and TIMPs. Protein expressions are depicted according to a color scale: red: positive staining; green: negative staining; gray: missing data. At right bank of the figure is represented the overall survival status for each patient (0, alive; 1, death due tumor progression).

The unsupervised hierarchical cluster analysis of MMPs/TIMPs expressions in HCCs led us to identify 2 well-defined clusters of cases (Figure 3): one with low expression of MMPs and TIMPs (Group 1), and another with high expression of these factors (Group 2). This classification could have biological interest in order to identify patient candidates to new therapies based on enzymatic MMP inhibition. With regard to this, although there are no published data about use of MMP inhibitors in HCC, recently it has been reported that decreased MMP activity mediated by statins reduced progression and limits metastatic diffusion of established HCC [118]. Likewise, it was demonstrated that blocking the tumor-related glycoprotein HAb18G/CD147 by gene silence in HCC cells or with HA18 monoclonal antibody, resulted in a suppressive effect on MMP secretion and cell invasion [119]. More recent studies have shown an antimetastatic effect of Norcantharidin on HCC by transcriptional inhibition of MMP-9 [120], as well as a metastasis inhibition of HCC cells due to down-regulation of Osteopontin via a mechanism involving MMP-2 and urinary plasminogen activator (uPA) [121].

6. Conclusion

In summary, we consider that expression analysis of steroid hormone receptors, MMPs and TIMPs, contributes to a better knowledge in the biological characterization of HCC and highlights the need for further studies exploring new therapeutic targets for this common tumor.

Author details

Noemí Eiró, Belen Fernandez-Garcia, Antonio Altadill, Luis O. González and Francisco J. Vizoso*

*Address all correspondence to: fjvizoso@terra.es

Unidad de Investigación. Fundación Hospital de Jove. Gijón, Asturias, Spain

References

- [1] Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. *CA Cancer J Clin* 55 (2):74-108. [PubMed: 15761078]
- [2] Nordenstedt H, White DL, El-Serag HB (2010) The changing pattern of epidemiology in hepatocellular carcinoma. *Dig Liver Dis* 42 Suppl 3:S206-214. [PubMed: 20547305]
- [3] El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. *N Engl J Med* 340 (10):745-750. [PubMed: 10072408]

- [4] Poon RT, Ng IO, Fan ST, Lai EC, Lo CM, Liu CL, Wong J (2001) Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. *J Clin Oncol* 19 (12):3037-3044. [PubMed: 11408499]
- [5] Kato A, Miyazaki M, Ambiru S, Yoshitomi H, Ito H, Nakagawa K, Shimizu H, Yokosuka O, Nakajima N (2001) Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. *J Surg Oncol* 78 (2):110-115. [PubMed: 11579388]
- [6] Yu MC, Yuan JM (2004) Environmental factors and risk for hepatocellular carcinoma. *Gastroenterology* 127 (5 Suppl 1):S72-78. [PubMed: 15508106]
- [7] Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS (2005) Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. *J Hepatol* 42 (2):218-224. [PubMed: 15664247]
- [8] Ohishi W, Fujiwara S, Cologne JB, Suzuki G, Akahoshi M, Nishi N, Takahashi I, Chayama K (2008) Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study. *Cancer Epidemiol Biomarkers Prev* 17 (4):846-854. [PubMed: 18398026]
- [9] Shimizu I, Kohno N, Tamaki K, Shono M, Huang HW, He JH, Yao DF (2007) Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection. *World J Gastroenterol* 13 (32):4295-4305. [PubMed: 17708600]
- [10] Shimizu I (2003) Impact of oestrogens on the progression of liver disease. *Liver Int* 23 (1):63-69. [PubMed: 12640729]
- [11] Fechner RE (1977) Benign hepatic lesions and orally administered contraceptives. A report of seven cases and a critical analysis of the literature. *Hum Pathol* 8 (3):255-268. [PubMed: 192659]
- [12] Vana J, Murphy GP, Aronoff BL, Baker HW (1977) Primary liver tumors and oral contraceptives. Results of a survey. *JAMA* 238 (20):2154-2158. [PubMed: 199752]
- [13] Kemp CJ, Leary CN, Drinkwater NR (1989) Promotion of murine hepatocarcinogenesis by testosterone is androgen receptor-dependent but not cell autonomous. *Proc Natl Acad Sci U S A* 86 (19):7505-7509. [PubMed: 2798421]
- [14] Poole TM, Drinkwater NR (1995) Hormonal and genetic interactions in murine hepatocarcinogenesis. *Prog Clin Biol Res* 391:187-194. [PubMed: 8532716]
- [15] Nakatani T, Roy G, Fujimoto N, Asahara T, Ito A (2001) Sex hormone dependency of diethylnitrosamine-induced liver tumors in mice and chemoprevention by leuprolin. *Jpn J Cancer Res* 92 (3):249-256. [PubMed: 11267934]
- [16] Yamamoto R, Iishi H, Tatsuta M, Yamamoto T, Koike K, Kanda Y, Miyake A, Tsuji M, Terada N (1995) Correlation between serum prolactin levels and hepatocellular

- tumorigenesis induced by 3'-methyl-4-dimethylaminoazobenzene in mice. *Br J Cancer* 72 (1):17-21. [PubMed: 7599048]
- [17] Ormandy CJ, Binart N, Helloco C, Kelly PA (1998) Mouse prolactin receptor gene: genomic organization reveals alternative promoter usage and generation of isoforms via alternative 3'-exon splicing. *DNA Cell Biol* 17 (9):761-770. [PubMed: 9778035]
- [18] Bigsby RM, Caperell-Grant A (2011) The role for estrogen receptor-alpha and prolactin receptor in sex-dependent DEN-induced liver tumorigenesis. *Carcinogenesis* 32 (8):1162-1166. [PubMed: 21606321]
- [19] Pettersson K, Gustafsson JA (2001) Role of estrogen receptor beta in estrogen action. *Annu Rev Physiol* 63:165-192. [PubMed: 11181953]
- [20] Gavrilova-Jordan LP, Price TM (2007) Actions of steroids in mitochondria. *Semin Reprod Med* 25 (3):154-164. [PubMed: 17447205]
- [21] Boonyaratanakornkit V, Edwards DP (2007) Receptor mechanisms mediating non-genomic actions of sex steroids. *Semin Reprod Med* 25 (3):139-153. [PubMed: 17447204]
- [22] Kalra M, Mayes J, Assefa S, Kaul AK, Kaul R (2008) Role of sex steroid receptors in pathobiology of hepatocellular carcinoma. *World J Gastroenterol* 14 (39):5945-5961. [PubMed: 18932272]
- [23] Vizoso FJ, Rodriguez M, Altadill A, Gonzalez-Dieguez ML, Linares A, Gonzalez LO, Junquera S, Fresno-Forcelledo F, Corte MD, Rodrigo L (2007) Liver expression of steroid hormones and Apolipoprotein D receptors in hepatocellular carcinoma. *World J Gastroenterol* 13 (23):3221-3227. [PubMed: 17589901]
- [24] Nagasue N, Kohno H, Chang YC, Yamanoi A, Nakamura T, Yukaya H, Hayashi T (1990) Clinicopathologic comparisons between estrogen receptor-positive and -negative hepatocellular carcinomas. *Ann Surg* 212 (2):150-154. [PubMed: 2165386]
- [25] Jonas S, Bechstein WO, Heinze T, Kling N, Lobeck H, Tullius SG, Steinmueller T, Neuhaus P (1997) Female sex hormone receptor status in advanced hepatocellular carcinoma and outcome after surgical resection. *Surgery* 121 (4):456-461. [PubMed: 9122877]
- [26] Villa E, Moles A, Ferretti I, Buttafoco P, Grottola A, Del Buono M, De Santis M, Manenti F (2000) Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. *Hepatology* 32 (2):233-238. [PubMed: 10915729]
- [27] Nagasue N, Chang YC, Hayashi T, Galizia G, Kohno H, Nakamura T, Yukaya H (1989) Androgen receptor in hepatocellular carcinoma as a prognostic factor after hepatic resection. *Ann Surg* 209 (4):424-427. [PubMed: 2539062]
- [28] Boix L, Castells A, Bruix J, Sole M, Bru C, Fuster J, Rivera F, Rodes J (1995) Androgen receptors in hepatocellular carcinoma and surrounding liver: relationship with tu-

- p mor size and recurrence rate after surgical resection.
- J Hepatol*
- 22 (6):616-622. [PubMed: 7560855]
- [29] Zhang X, He L, Lu Y, Liu M, Huang X (1998) Androgen receptor in primary hepatocellular carcinoma and its clinical significance. *Chin Med J (Engl)* 111 (12):1083-1086. [PubMed: 11263369]
 - [30] Villa E, Dugani A, Fantoni E, Camellini L, Buttafoco P, Grottola A, Pompei G, De Santis M, Ferrari A, Manenti F (1996) Type of estrogen receptor determines response to antiestrogen therapy. *Cancer Res* 56 (17):3883-3885. [PubMed: 8752151]
 - [31] Han J, Ding L, Yuan B, Yang X, Wang X, Li J, Lu Q, Huang C, Ye Q (2006) Hepatitis B virus X protein and the estrogen receptor variant lacking exon 5 inhibit estrogen receptor signaling in hepatoma cells. *Nucleic Acids Res* 34 (10):3095-3106. [PubMed: 16757575]
 - [32] Watashi K, Inoue D, Hijikata M, Goto K, Aly HH, Shimotohno K (2007) Anti-hepatitis C virus activity of tamoxifen reveals the functional association of estrogen receptor with viral RNA polymerase NS5B. *J Biol Chem* 282 (45):32765-32772. [PubMed: 17704057]
 - [33] Yu MW, Yang YC, Yang SY, Cheng SW, Liaw YF, Lin SM, Chen CJ (2001) Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. *J Natl Cancer Inst* 93 (21):1644-1651. [PubMed: 11698569]
 - [34] Yu MW, Cheng SW, Lin MW, Yang SY, Liaw YF, Chang HC, Hsiao TJ, Lin SM, Lee SD, Chen PJ, Liu CJ, Chen CJ (2000) Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. *J Natl Cancer Inst* 92 (24):2023-2028. [PubMed: 11121465]
 - [35] Wang N, Zheng Y, Yu X, Lin W, Chen Y, Jiang Q (2009) Sex-modified effect of hepatitis B virus infection on mortality from primary liver cancer. *Am J Epidemiol* 169 (8): 990-995. [PubMed: 19224979]
 - [36] Wu MH, Ma WL, Hsu CL, Chen YL, Ou JH, Ryan CK, Hung YC, Yeh S, Chang C (2010) Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. *Sci Transl Med* 2 (32): 32ra35. [PubMed: 20484730]
 - [37] Colleoni M, Nelli P, Vicario G, Mastropasqua G, Manente P (1995) Megestrol acetate in unresectable hepatocellular carcinoma. *Tumori* 81 (5):351-353. [PubMed: 8804452]
 - [38] Chao Y, Chan WK, Huang YS, Teng HC, Wang SS, Lui WY, Whang-Peng J, Lee SD (1996) Phase II study of flutamide in the treatment of hepatocellular carcinoma. *Cancer* 77 (4):635-639. [PubMed: 8616754]
 - [39] Randomized trial of leuporelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen (2004). *Hepatology* 40 (6):1361-1369. [PubMed: 15565568]

- [40] Ruden DM, Xiao L, Garfinkel MD, Lu X (2005) Hsp90 and environmental impacts on epigenetic states: a model for the trans-generational effects of diethylstilbestrol on uterine development and cancer. *Hum Mol Genet* 14 Spec No 1:R149-155. [PubMed: 15809267]
- [41] Di Maio M, De Maio E, Morabito A, D'Aniello R, De Feo G, Gallo C, Perrone F (2006) Hormonal treatment of human hepatocellular carcinoma. *Ann N Y Acad Sci* 1089:252-261. [PubMed: 17261772]
- [42] Di Maio M, Daniele B, Pignata S, Gallo C, De Maio E, Morabito A, Piccirillo MC, Perrone F (2008) Is human hepatocellular carcinoma a hormone-responsive tumor? *World J Gastroenterol* 14 (11):1682-1689. [PubMed: 18350599]
- [43] Bryant HU, Dere WH (1998) Selective estrogen receptor modulators: an alternative to hormone replacement therapy. *Proc Soc Exp Biol Med* 217 (1):45-52. [PubMed: 9421206]
- [44] Grese TA, Dodge JA (1998) Selective estrogen receptor modulators (SERMs). *Curr Pharm Des* 4 (1):71-92. [PubMed: 10197034]
- [45] Fournier B, Gutzwiller S, Dittmar T, Matthias G, Steenbergh P, Matthias P (2001) Estrogen receptor (ER)-alpha, but not ER-beta, mediates regulation of the insulin-like growth factor I gene by antiestrogens. *J Biol Chem* 276 (38):35444-35449. [PubMed: 11457856]
- [46] Stendahl M, Ryden L, Nordenskjold B, Jonsson PE, Landberg G, Jirstrom K (2006) High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. *Clin Cancer Res* 12 (15):4614-4618. [PubMed: 16899609]
- [47] Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ (2006) The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. *Cancer* 106 (12): 2576-2582. [PubMed: 16703595]
- [48] Eagon PK, Elm MS, Epley MJ, Shinozuka H, Rao KN (1996) Sex steroid metabolism and receptor status in hepatic hyperplasia and cancer in rats. *Gastroenterology* 110 (4):1199-1207. [PubMed: 8613010]
- [49] Nagasue N, Yu L, Yukaya H, Kohno H, Nakamura T (1995) Androgen and oestrogen receptors in hepatocellular carcinoma and surrounding liver parenchyma: impact on intrahepatic recurrence after hepatic resection. *Br J Surg* 82 (4):542-547. [PubMed: 7613907]
- [50] Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, Ellis TM, Wojcik EM, Yang D, Flanigan RC, Waters WB, Kast WM, Kwon ED (2001) T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. *Proc Natl Acad Sci U S A* 98 (25):14565-14570. [PubMed: 11734652]

- [51] Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA (2009) Inflammation and liver cancer: new molecular links. *Ann N Y Acad Sci* 1155:206-221. [PubMed: 19250206]
- [52] Boix L, Bruix J, Castells A, Fuster J, Bru C, Visa J, Rivera F, Rodes J (1993) Sex hormone receptors in hepatocellular carcinoma. Is there a rationale for hormonal treatment? *J Hepatol* 17 (2):187-191. [PubMed: 8383159]
- [53] Simard J, Dauvois S, Haagensen DE, Levesque C, Merand Y, Labrie F (1990) Regulation of progesterone-binding breast cyst protein GCDP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer. *Endocrinology* 126 (6):3223-3231. [PubMed: 2351114]
- [54] Simard J, de Launoit Y, Haagensen DE, Labrie F (1992) Additive stimulatory action of glucocorticoids and androgens on basal and estrogen-repressed apolipoprotein-D messenger ribonucleic acid levels and secretion in human breast cancer cells. *Endocrinology* 130 (3):1115-1121. [PubMed: 1537279]
- [55] Sugimoto K, Simard J, Haagensen DE, Labrie F (1994) Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells. *J Steroid Biochem Mol Biol* 51 (3-4):167-174. [PubMed: 7526888]
- [56] Utsunomiya T, Ogawa K, Yoshinaga K, Ohta M, Yamashita K, Mimori K, Inoue H, Ezaki T, Yoshikawa Y, Mori M (2005) Clinicopathologic and prognostic values of apolipoprotein D alterations in hepatocellular carcinoma. *Int J Cancer* 116 (1):105-109. [PubMed: 15756681]
- [57] Lopez-Boado YS, Tolivia J, Lopez-Otin C (1994) Apolipoprotein D gene induction by retinoic acid is concomitant with growth arrest and cell differentiation in human breast cancer cells. *J Biol Chem* 269 (43):26871-26878. [PubMed: 7929425]
- [58] Lopez-Boado YS, Diez-Itza I, Tolivia J, Lopez-Otin C (1994) Glucocorticoids and androgens up-regulate the Zn-alpha 2-glycoprotein messenger RNA in human breast cancer cells. *Breast Cancer Res Treat* 29 (3):247-258. [PubMed: 8049458]
- [59] P'Eng F K, Lui WY, Chang TJ, Kao HL, Wu LH, Liu TY, Chi CW (1988) Glucocorticoid receptors in hepatocellular carcinoma and adjacent liver tissue. *Cancer* 62 (10):2134-2138. [PubMed: 2460210]
- [60] Sano K, Takayama T, Murakami K, Saiki I, Makuuchi M (2003) Overexpression of retinoic acid receptor alpha in hepatocellular carcinoma. *Clin Cancer Res* 9 (10 Pt 1):3679-3683. [PubMed: 14506158]
- [61] Clerici C, Castellani D, Russo G, Fiorucci S, Sabatino G, Giuliano V, Gentili G, Morelli O, Raffo P, Baldoni M, Morelli A, Toma S (2004) Treatment with all-trans retinoic acid plus tamoxifen and vitamin E in advanced hepatocellular carcinoma. *Anticancer Res* 24 (2C):1255-1260. [PubMed: 15154656]

- [62] Diez-Itza I, Sanchez LM, Allende MT, Vizoso F, Ruibal A, Lopez-Otin C (1993) Zn-alpha 2-glycoprotein levels in breast cancer cytosols and correlation with clinical, histological and biochemical parameters. *Eur J Cancer* 29A (9):1256-1260. [PubMed: 8343263]
- [63] Huang Y, Li LZ, Zhang CZ, Yi C, Liu LL, Zhou X, Xie GB, Cai MY, Li Y, Yun JP (2012) Decreased expression of zinc-alpha2-glycoprotein in hepatocellular carcinoma associates with poor prognosis. *J Transl Med* 10 (1):106. [PubMed: 22625427]
- [64] Xu H, Wei Y, Zhang Y, Xu Y, Li F, Liu J, Zhang W, Han X, Tan R, Shen P (2012) Oestrogen attenuates tumour progression in hepatocellular carcinoma. *J Pathol* 228 (2): 216-229. [PubMed: 22374713]
- [65] Gold SM, Sasidhar MV, Morales LB, Du S, Sicotte NL, Tiwari-Woodruff SK, Voskuhl RR (2009) Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERalpha). *Lab Invest* 89 (10):1076-1083. [PubMed: 19668239]
- [66] Claassen H, Steffen R, Hassenpflug J, Varoga D, Wruck CJ, Brandenburg LO, Pufe T (2010) 17beta-estradiol reduces expression of MMP-1, -3, and -13 in human primary articular chondrocytes from female patients cultured in a three dimensional alginate system. *Cell Tissue Res* 342 (2):283-293. [PubMed: 20941509]
- [67] Zhou H, Kimura K, Orita T, Nishida T, Sonoda KH (2011) Inhibition by female sex hormones of collagen degradation by corneal fibroblasts. *Mol Vis* 17:3415-3422. [PubMed: 22219637]
- [68] Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biologic activity and clinical implications. *J Clin Oncol* 18 (5):1135-1149. [PubMed: 10694567]
- [69] McCawley LJ, Matrisian LM (2001) Matrix metalloproteinases: they're not just for matrix anymore! *Curr Opin Cell Biol* 13 (5):534-540. [PubMed: 11544020]
- [70] Demers M, Couillard J, Belanger S, St-Pierre Y (2005) New roles for matrix metalloproteinases in metastasis. *Crit Rev Immunol* 25 (6):493-523. [PubMed: 16390324]
- [71] Brinckerhoff CE, Rutter JL, Benbow U (2000) Interstitial collagenases as markers of tumor progression. *Clin Cancer Res* 6 (12):4823-4830. [PubMed: 11156241]
- [72] Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. *Annu Rev Cell Dev Biol* 17:463-516. [PubMed: 11687497]
- [73] Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. *Nat Rev Cancer* 2 (3):161-174. [PubMed: 11990853]
- [74] Turk V, Kos J, Turk B (2004) Cysteine cathepsins (proteases)--on the main stage of cancer? *Cancer Cell* 5 (5):409-410. [PubMed: 15144947]

- [75] Rifkin DB, Mazzei R, Munger JS, Noguera I, Sung J (1999) Proteolytic control of growth factor availability. *APMIS* 107 (1):80-85. [PubMed: 10190283]
- [76] Manes S, Llorente M, Lacalle RA, Gomez-Mouton C, Kremer L, Mira E, Martinez AC (1999) The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. *J Biol Chem* 274 (11):6935-6945. [PubMed: 10066747]
- [77] Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel M (2001) Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. *J Cell Sci* 114 (Pt 1):111-118. [PubMed: 11112695]
- [78] Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM (2001) Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. *Neoplasia* 3 (6):459-468. [PubMed: 11774028]
- [79] Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. *Genes Dev* 14 (2):163-176. [PubMed: 10652271]
- [80] Stetler-Stevenson WG (1999) Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. *J Clin Invest* 103 (9):1237-1241. [PubMed: 10225966]
- [81] Dong Z, Kumar R, Yang X, Fidler IJ (1997) Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. *Cell* 88 (6):801-810. [PubMed: 9118223]
- [82] Cornelius LA, Nehring LC, Harding E, Bolanowski M, Welgus HG, Kobayashi DK, Pierce RA, Shapiro SD (1998) Matrix metalloproteinases generate angiostatin: effects on neovascularization. *J Immunol* 161 (12):6845-6852. [PubMed: 9862716]
- [83] Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J (2000) Generation and degradation of human endostatin proteins by various proteinases. *FEBS Lett* 486 (3):247-251. [PubMed: 11119712]
- [84] Jiang Y, Goldberg ID, Shi YE (2002) Complex roles of tissue inhibitors of metalloproteinases in cancer. *Oncogene* 21 (14):2245-2252. [PubMed: 11948407]
- [85] Baker AH, George SJ, Zaltsman AB, Murphy G, Newby AC (1999) Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. *Br J Cancer* 79 (9-10):1347-1355. [PubMed: 10188875]
- [86] Yamamoto H, Itoh F, Adachi Y, Sakamoto H, Adachi M, Hinoda Y, Imai K (1997) Relation of enhanced secretion of active matrix metalloproteinases with tumor spread in human hepatocellular carcinoma. *Gastroenterology* 112 (4):1290-1296. [PubMed: 9098015]
- [87] Theret N, Musso O, Turlin B, Lotrian D, Bioulac-Sage P, Campion JP, Boudjema K, Clement B (2001) Increased extracellular matrix remodeling is associated with tumor

- progression in human hepatocellular carcinomas. *Hepatology* 34 (1):82-88. [PubMed: 11431737]
- [88] Ishii Y, Nakasato Y, Kobayashi S, Yamazaki Y, Aoki T (2003) A study on angiogenesis-related matrix metalloproteinase networks in primary hepatocellular carcinoma. *J Exp Clin Cancer Res* 22 (3):461-470. [PubMed: 14582707]
- [89] McKenna GJ, Chen Y, Smith RM, Meneghetti A, Ong C, McMaster R, Scudamore CH, Chung SW (2002) A role for matrix metalloproteinases and tumor host interaction in hepatocellular carcinomas. *Am J Surg* 183 (5):588-594. [PubMed: 12034400]
- [90] Sawada S, Murakami K, Murata J, Tsukada K, Saiki I (2001) Accumulation of extracellular matrix in the liver induces high metastatic potential of hepatocellular carcinoma to the lung. *Int J Oncol* 19 (1):65-70. [PubMed: 11408924]
- [91] Maatta M, Soini Y, Liakka A, Autio-Harmainen H (2000) Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. *Clin Cancer Res* 6 (7):2726-2734. [PubMed: 10914717]
- [92] Cui J, Dong BW, Liang P, Yu XL, Yu DJ (2004) Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection. *World J Gastroenterol* 10 (10):1533-1536. [PubMed: 15133868]
- [93] Zhang Q, Chen X, Zhou J, Zhang L, Zhao Q, Chen G, Xu J, Qian F, Chen Z (2006) CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. *Cancer Biol Ther* 5 (7):808-814. [PubMed: 16775432]
- [94] Gao ZH, Tretiakova MS, Liu WH, Gong C, Farris PD, Hart J (2006) Association of E-cadherin, matrix metalloproteinases, and tissue inhibitors of metalloproteinases with the progression and metastasis of hepatocellular carcinoma. *Mod Pathol* 19 (4):533-540. [PubMed: 16474379]
- [95] Arii S, Mise M, Harada T, Furutani M, Ishigami S, Niwano M, Mizumoto M, Fukumoto M, Imamura M (1996) Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. *Hepatology* 24 (2):316-322. [PubMed: 8690399]
- [96] Hayasaka A, Suzuki N, Fujimoto N, Iwama S, Fukuyama E, Kanda Y, Saisho H (1996) Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. *Hepatology* 24 (5):1058-1062. [PubMed: 8903375]
- [97] Sakamoto Y, Mafune K, Mori M, Shiraishi T, Imamura H, Takayama T, Makuuchi M (2000) Overexpression of MMP-9 correlates with growth of small hepatocellular carcinoma. *Int J Oncol* 17 (2):237-243. [PubMed: 10891530]
- [98] Harada T, Arii S, Mise M, Imamura T, Higashitsuji H, Furutani M, Niwano M, Ishigami S, Fukumoto M, Seiki M, Sato H, Imamura M (1998) Membrane-type matrix

- metalloproteinase-1(MT1-MTP) gene is overexpressed in highly invasive hepatocellular carcinomas. *J Hepatol* 28 (2):231-239. [PubMed: 9514536]
- [99] Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J, Dudoit S, Ng IO, Van De Rijn M, Botstein D, Brown PO (2002) Gene expression patterns in human liver cancers. *Mol Biol Cell* 13 (6):1929-1939. [PubMed: 12058060]
- [100] Ip YC, Cheung ST, Leung KL, Fan ST (2005) Mechanism of metastasis by membrane type 1-matrix metalloproteinase in hepatocellular carcinoma. *World J Gastroenterol* 11 (40):6269-6276. [PubMed: 16419154]
- [101] Bosch FX, Ribes J, Borrás J (1999) Epidemiology of primary liver cancer. *Semin Liver Dis* 19 (3):271-285. [PubMed: 10518307]
- [102] Poon RT, Fan ST, Lo CM, Liu CL, Ng IO, Wong J (2000) Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. *J Clin Oncol* 18 (5):1094-1101. [PubMed: 10694562]
- [103] Giannelli G, Bergamini C, Fransvea E, Marinosci F, Quaranta V, Antonaci S (2001) Human hepatocellular carcinoma (HCC) cells require both $\alpha 3 \beta 1$ integrin and matrix metalloproteinases activity for migration and invasion. *Lab Invest* 81 (4): 613-627. [PubMed: 11304581]
- [104] Chen R, Cui J, Xu C, Xue T, Guo K, Gao D, Liu Y, Ye S, Ren Z (2012) The Significance of MMP-9 Over MMP-2 in HCC Invasiveness and Recurrence of Hepatocellular Carcinoma After Curative Resection. *Ann Surg Oncol* 19 Suppl 3:375-384. [PubMed: 21681378]
- [105] Ng KT, Qi X, Kong KL, Cheung BY, Lo CM, Poon RT, Fan ST, Man K (2011) Overexpression of matrix metalloproteinase-12 (MMP-12) correlates with poor prognosis of hepatocellular carcinoma. *Eur J Cancer* 47 (15):2299-2305. [PubMed: 21683576]
- [106] Stamenkovic I (2000) Matrix metalloproteinases in tumor invasion and metastasis. *Semin Cancer Biol* 10 (6):415-433. [PubMed: 11170864]
- [107] Akriviadis EA, Llovet JM, Efremidis SC, Shouval D, Canelo R, Ringe B, Meyers WC (1998) Hepatocellular carcinoma. *Br J Surg* 85 (10):1319-1331. [PubMed: 9782009]
- [108] Ozaki T, Mochizuki H, Ichikawa Y, Fukuzawa Y, Yoshida S, Morimoto M (2000) Persistence of hepatitis B surface antibody levels after vaccination with a recombinant hepatitis B vaccine: a 3-year follow-up study. *J Oral Sci* 42 (3):147-150. [PubMed: 11111325]
- [109] Milani S, Herbst H, Schuppan D, Grappone C, Pellegrini G, Pinzani M, Casini A, Calabro A, Ciancio G, Stefanini F, et al. (1994) Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver. *Am J Pathol* 144 (3): 528-537. [PubMed: 8129038]

- [110] Benyon RC, Iredale JP, Goddard S, Winwood PJ, Arthur MJ (1996) Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. *Gastroenterology* 110 (3):821-831. [PubMed: 8608892]
- [111] Kapranos N, Karaiossifidi H, Kouri E, Vasilaros S (1996) Nm23 expression in breast ductal carcinomas: a ten year follow-up study in a uniform group of node-negative breast cancer patients. *Anticancer Res* 16 (6C):3987-3990. [PubMed: 9042324]
- [112] Takahara T, Furui K, Yata Y, Jin B, Zhang LP, Nambu S, Sato H, Seiki M, Watanabe A (1997) Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers. *Hepatology* 26 (6):1521-1529. [PubMed: 9397993]
- [113] Altadill A, Rodriguez M, Gonzalez LO, Junquera S, Corte MD, Gonzalez-Dieguez ML, Linares A, Barbon E, Fresno-Forcelledo M, Rodrigo L, Vizoso FJ (2009) Liver expression of matrix metalloproteases and their inhibitors in hepatocellular carcinoma. *Dig Liver Dis* 41 (10):740-748. [PubMed: 19372066]
- [114] Preaux AM, Mallat A, Nhieu JT, D'Ortho MP, Hembry RM, Mavrier P (1999) Matrix metalloproteinase-2 activation in human hepatic fibrosis regulation by cell-matrix interactions. *Hepatology* 30 (4):944-950. [PubMed: 10498646]
- [115] Nakatsukasa H, Ashida K, Higashi T, Ohguchi S, Tsuboi S, Hino N, Nouse K, Urabe Y, Kinugasa N, Yoshida K, Uematsu S, Ishizaki M, Kobayashi Y, Tsuji T (1996) Cellular distribution of transcripts for tissue inhibitor of metalloproteinases 1 and 2 in human hepatocellular carcinomas. *Hepatology* 24 (1):82-88. [PubMed: 8707287]
- [116] Zhang H, Wang YS, Han G, Shi Y (2007) TIMP-3 gene transfection suppresses invasive and metastatic capacity of human hepatocarcinoma cell line HCC-7721. *Hepatobiliary Pancreat Dis Int* 6 (5):487-491. [PubMed: 17897911]
- [117] Roeb E, Bosserhoff AK, Hamacher S, Jansen B, Dahmen J, Wagner S, Matern S (2005) Enhanced migration of tissue inhibitor of metalloproteinase overexpressing hepatoma cells is attributed to gelatinases: relevance to intracellular signaling pathways. *World J Gastroenterol* 11 (8):1096-1104. [PubMed: 15754388]
- [118] Taras D, Blanc JF, Rullier A, Dugot-Senant N, Laurendeau I, Vidaud M, Rosenbaum J (2007) Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. *J Hepatol* 46 (1):69-76. [PubMed: 16935385]
- [119] Xu J, Xu HY, Zhang Q, Song F, Jiang JL, Yang XM, Mi L, Wen N, Tian R, Wang L, Yao H, Feng Q, Zhang Y, Xing JL, Zhu P, Chen ZN (2007) HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. *Mol Cancer Res* 5 (6):605-614. [PubMed: 17579119]
- [120] Yeh CB, Hsieh MJ, Hsieh YH, Chien MH, Chiou HL, Yang SF (2012) Antimetastatic effects of norcantharidin on hepatocellular carcinoma by transcriptional inhibition of

- MMP-9 through modulation of NF- κ B activity. *PLoS One* 7 (2):e31055. [PubMed: 22363545]
- [121] Chen RX, Xia YH, Xue TC, Zhang H, Ye SL (2011) Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA. *Oncol Rep* 25 (3):803-808. [PubMed: 21174062]
- [122] Duffy MJ, Duffy GJ (1978) Estradiol receptors in human liver. *J Steroid Biochem* 9 (3): 233-235. [PubMed: 651349]
- [123] Macdonald JS, Lippman ME, Woolley PV, Petrucci PP, Schein PS (1978) Hepatic estrogen and progesterone receptors in an estrogen-associated hepatic neoplasm. *Cancer Chemother Pharmacol* 1 (3):135-138. [PubMed: 373914]
- [124] Friedman MA, Demanes DJ, Hoffman PG, Jr. (1982) Hepatomas: hormone receptors and therapy. *Am J Med* 73 (3):362-366. [PubMed: 6289660]
- [125] Bojar H, Schutte J, Staib W, Broelsch C (1982) Does human liver contain estrogen receptors? A comparative study of estrogen binding in human and rodent liver. *Klin Wochenschr* 60 (8):417-425. [PubMed: 7098385]
- [126] Porter LE, Elm MS, Van Thiel DH, Dugas MC, Eagon PK (1983) Characterization and quantitation of human hepatic estrogen receptor. *Gastroenterology* 84 (4):704-712. [PubMed: 6825981]
- [127] Iqbal MJ, Wilkinson ML, Johnson PJ, Williams R (1983) Sex steroid receptor proteins in foetal, adult and malignant human liver tissue. *Br J Cancer* 48 (6):791-796. [PubMed: 6317004]
- [128] Nagasue N, Ito A, Yukaya H, Ogawa Y (1986) Estrogen receptors in hepatocellular carcinoma. *Cancer* 57 (1):87-91. [PubMed: 3000573]
- [129] Negro F, Papotti M, Pacchioni D, Galimi F, Bonino F, Bussolati G (1994) Detection of human androgen receptor mRNA in hepatocellular carcinoma by in situ hybridisation. *Liver* 14 (4):213-219. [PubMed: 7968281]
- [130] Kohigashi K, Fukuda Y, Imura H (1987) Estrogen receptors in hepatocellular carcinoma: is endocrine therapy for hepatocellular carcinoma likely to be effective? *Gastroenterol Jpn* 22 (3):322-330. [PubMed: 3040510]
- [131] Ohnami S, Nakata H, Nagafuchi Y, Zeze F, Eto S (1988) [Estrogen receptors in human gastric, hepatocellular, and gallbladder carcinomas and normal liver tissues]. *Gan To Kagaku Ryoho* 15 (10):2923-2928. [PubMed: 2845868]
- [132] Nagasue N, Kohno H, Chang YC, Hayashi T, Utsumi Y, Nakamura T, Yukaya H (1989) Androgen and estrogen receptors in hepatocellular carcinoma and the surrounding liver in women. *Cancer* 63 (1):112-116. [PubMed: 2535950]

- [133] Hamazaki K, Miura H, Sakai H, Sato S, Yunoki M, Miichi N, Noda T, Mori M, Orita K (1989) [Estrogen and androgen receptors in hepatocellular carcinoma and in non-cancerous liver tissue]. *Gan No Rinsho* 35 (10):1109-1113. [PubMed: 2550681]
- [134] Nagasue N, Kohno H, Chang Y, Hayashi T, Nakamura T (1990) Specificity of androgen receptors of hepatocellular carcinoma and liver in humans. *Hepatogastroenterology* 37 (5):474-479. [PubMed: 2174826]
- [135] Eagon PK, Francavilla A, DiLeo A, Elm MS, Gennari L, Mazzaferro V, Colella G, Van Thiel DH, Strazl TE (1991) Quantitation of estrogen and androgen receptors in hepatocellular carcinoma and adjacent normal human liver. *Dig Dis Sci* 36 (9):1303-1308. [PubMed: 1654243]
- [136] Pacchioni D, Papotti M, Andorno E, Bonino F, Mondardini A, Oliveri F, Brunetto M, Bussolati G, Negro F (1993) Expression of estrogen receptor mRNA in tumorous and non-tumorous liver tissue as detected by in situ hybridization. *J Surg Oncol Suppl* 3:14-17. [PubMed: 8389161]
- [137] Wang AG, Lee KY, Kim SY, Choi JY, Lee KH, Kim WH, Wang HJ, Kim JM, Park MG, Yeom YI, Kim NS, Yu DY, Lee DS (2006) The expression of estrogen receptors in hepatocellular carcinoma in Korean patients. *Yonsei Med J* 47 (6):811-816. [PubMed: 17191310]
- [138] Wong LY, Chan SH, Oon CJ, Rauff A (1984) Immunocytochemical localization of testosterone in human hepatocellular carcinoma. *Histochem J* 16 (6):687-692. [PubMed: 6330003]
- [139] Ohnishi S, Murakami T, Moriyama T, Mitamura K, Imawari M (1986) Androgen and estrogen receptors in hepatocellular carcinoma and in the surrounding noncancerous liver tissue. *Hepatology* 6 (3):440-443. [PubMed: 3011631]
- [140] Nagasue N, Kohno H, Yamanoi A, Kimoto T, Chang YC, Nakamura T (1991) Progesterone receptor in hepatocellular carcinoma. Correlation with androgen and estrogen receptors. *Cancer* 67 (10):2501-2505. [PubMed: 1849788]
- [141] Francavilla A, Panella C, Amoruso A, Giangaspero A, Gennari L, Mazzaferro V, Colella G, Van Thiel DH, Starzl TE (1991) Role of estrogens and epidermal growth factor in hepatocellular carcinoma (HCC). *Dig Dis Sci* 36 (9):1299-1302. [PubMed: 1654242]
- [142] Villa E, Camellini L, Dugani A, Zucchi F, Grottola A, Merighi A, Buttafoco P, Losi L, Manenti F (1995) Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. *Cancer Res* 55 (3):498-500. [PubMed: 7834616]
- [143] Ng IO, Ng M, Fan ST (1997) Better survival in women with resected hepatocellular carcinoma is not related to tumor proliferation or expression of hormone receptors. *Am J Gastroenterol* 92 (8):1355-1358. [PubMed: 9260806]

- [144] Villa E, Dugani A, Moles A, Camellini L, Grottola A, Buttafoco P, Merighi A, Ferretti I, Esposito P, Miglioli L, Bagni A, Troisi R, De Hemptinne B, Praet M, Callea F, Manenti F (1998) Variant liver estrogen receptor transcripts already occur at an early stage of chronic liver disease. *Hepatology* 27 (4):983-988. [PubMed: 9537437]
- [145] Iavarone M, Lampertico P, Seletti C, Francesca Donato M, Ronchi G, del Ninno E, Colombo M (2003) The clinical and pathogenetic significance of estrogen receptor-beta expression in chronic liver diseases and liver carcinoma. *Cancer* 98 (3):529-534. [PubMed: 12879470]
- [146] Moon WS, Chang K, Tarnawski AS (2004) Overexpression of metastatic tumor antigen 1 in hepatocellular carcinoma: Relationship to vascular invasion and estrogen receptor-alpha. *Hum Pathol* 35 (4):424-429. [PubMed: 15116322]
- [147] Xing BC, Wang JH, Wang Y, Hao CY, Huang XF (2004) [Expression of wild type and variant estrogen receptors in human hepatocellular carcinoma]. *Beijing Da Xue Xue Bao* 36 (6):620-622. [PubMed: 15605095]
- [148] Meza-Junco J, Montano-Loza AJ, Gamboa-Dominguez A, Green-Renner D (2007) Expression of oestrogen and growth factor receptors in hepatocellular carcinoma. *Clin Oncol (R Coll Radiol)* 19 (10):801-802. [PubMed: 17822888]
- [149] Nagasue N, Ito A, Yukaya H, Ogawa Y (1985) Androgen receptors in hepatocellular carcinoma and surrounding parenchyma. *Gastroenterology* 89 (3):643-647. [PubMed: 2991072]
- [150] Wilkinson ML, Iqbal MJ, Williams R (1985) Characterisation of high affinity binding sites of androgens in primary hepatocellular carcinoma. *Clin Chim Acta* 152 (1-2): 105-113. [PubMed: 2414040]
- [151] Bannister P, Meystre CM, Losowsky MS (1988) Androgen receptor concentrations in needle biopsy specimens of human liver. *Liver* 8 (1):28-31. [PubMed: 3367706]
- [152] Nagasue N, Yamanoi A, Kohno H, Kimoto T, Chang Y, Taniura H, Uchida M, Nakamura T (1992) Androgen receptor in cirrhotic liver, adenomatous hyperplastic nodule and hepatocellular carcinoma in the human. *Hepatogastroenterology* 39 (5): 455-460. [PubMed: 1334038]
- [153] Tavian D, De Petro G, Pitozzi A, Portolani N, Giulini SM, Barlati S (2002) Androgen receptor mRNA under-expression in poorly differentiated human hepatocellular carcinoma. *Histol Histopathol* 17 (4):1113-1119. [PubMed: 12371139]
- [154] Engstrom PF, Levin B, Moertel CG, Schutt A (1990) A phase II trial of tamoxifen in hepatocellular carcinoma. *Cancer* 65 (12):2641-2643. [PubMed: 2160313]
- [155] Castells A, Bruix J, Bru C, Ayuso C, Roca M, Boix L, Vilana R, Rodes J (1995) Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. *Gastroenterology* 109 (3):917-922. [PubMed: 7657122]

- [156] Liu CL, Fan ST, Ng IO, Lo CM, Poon RT, Wong J (2000) Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. *Am J Gastroenterol* 95 (1):218-222. [PubMed: 10638587]
- [157] Villa E, Ferretti I, Grottola A, Buttafoco P, Buono MG, Giannini F, Manno M, Bertani H, Dugani A, Manenti F (2001) Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. *Br J Cancer* 84 (7):881-885. [PubMed: 11286465]
- [158] Chow PK, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ, Soo KC (2002) High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. *Hepatology* 36 (5):1221-1226. [PubMed: 12395333]